Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 9/20 | 0.64 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.55 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.53 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.53 |
| ▸ | CASP2 | P42575 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9664722 | 1.00 | FAAH (0.64) | FAAHHSP90AA1MEN1KMT2ATP53 | |
| SCHEMBL5200631 | 1.00 | FAAH (0.64) | FAAHHSP90AA1MEN1KMT2ATP53 | |
| SCHEMBL29060568 | 1.00 | FAAH (0.64) | FAAHHSP90AA1MEN1KMT2ATP53 | |
| SCHEMBL9664822 | 1.00 | FAAH (0.64) | FAAHHSP90AA1MEN1KMT2ATP53 | |
| SCHEMBL9664810 | 1.00 | FAAH (0.64) | FAAHHSP90AA1MEN1KMT2ATP53 | |
| SCHEMBL7345186 | 0.98 | FAAH (0.61) | FAAHHSP90AA1MEN1KMT2ATP53 | |
| SCHEMBL23974151 | 0.96 | FAAH (0.60) | FAAHHSP90AA1MEN1KMT2ATP53 | |
| SCHEMBL3047227 | 0.96 | FAAH (0.60) | FAAHHSP90AA1MEN1KMT2ATP53 | |
| SCHEMBL23718538 | 0.96 | FAAH (0.60) | FAAHHSP90AA1MEN1KMT2ATP53 | |
| SCHEMBL21065315 | 0.94 | FAAH (0.57) | FAAHHSP90AA1MEN1KMT2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0473700-A1 | AN ENZYME-CATALYZED PROCESS FOR PREPARING N-ACYL AMINO ACIDS AND N-ACYL AMINO ACID AMIDES | NOVO NORDISK A/S (DK) | 1992-03-11 | — | — | EP | claimed |
| WO-1990014429-A1 | AN ENZYME-CATALYZED PROCESS FOR PREPARING N-ACYL AMINO ACIDS AND N-ACYL AMINO ACID AMIDES | NOVO NORDISK A/S (DK) | 1990-11-29 | — | — | WO | claimed |
| US-20210230466-A1 | PRODUCTS AND METHODS FOR THE TREATMENT OF MIXTURES OF WATER AND HYDROPHOBIC LIQUIDS | B.C. RESEARCH INC. (CA) | 2021-07-29 | — | — | US | disclosed |
| WO-2019232629-A1 | PRODUCTS AND METHODS FOR THE TREATMENT OF MIXTURES OF WATER AND HYDROPHOBIC LIQUIDS | B.C. RESEARCH INC. (CA) | 2019-12-12 | — | — | WO | disclosed |
| EP-1264589-A1 | Use of a polar additive in a cosmetic composition containing a structured liquid oil phase by at least one organogelator to give a thixotropic character | L'OREAL (FR) | 2002-12-11 | — | — | EP | disclosed |
| WO-2002005763-A1 | COSMETIC OR PHARMACEUTICAL COMPOSITION IN SOLID FORM COMPRISING BIS-ACYL-AMIDES | L'OREAL (FR) | 2002-01-24 | — | — | WO | disclosed |
| EP-1174110-A1 | Cosmetic or pharmaceutical solid composition comprising bis-acyl-amides | L'OREAL (FR) | 2002-01-23 | — | — | EP | disclosed |
| US-5432267-A | Inhibits tumor necrosis factor derivation by endotoxin | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1995-07-11 | — | — | US | disclosed |
| EP-0563908-A1 | Amino sugar derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1993-10-06 | — | — | EP | disclosed |
| EP-0473700-A1 | AN ENZYME-CATALYZED PROCESS FOR PREPARING N-ACYL AMINO ACIDS AND N-ACYL AMINO ACID AMIDES | NOVO NORDISK A/S (DK) | 1992-03-11 | — | — | EP | disclosed |
| WO-1990014429-A1 | AN ENZYME-CATALYZED PROCESS FOR PREPARING N-ACYL AMINO ACIDS AND N-ACYL AMINO ACID AMIDES | NOVO NORDISK A/S (DK) | 1990-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230466-A1 | PRODUCTS AND METHODS FOR THE TREATMENT OF MIXTURES OF WATER AND HYDROPHOBIC LIQUIDS | SLC43A1, FABP2, FABP1 | FAAH 148/4885HSP90AA1 271/4885MEN1 4306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.